Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Merck & Co., Inc. (MRK.BA)

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
5,400.00+210.00 (+4.05%)
At close: 04:58PM ART
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5,190.00
Open5,310.50
Bid5,190.00 x 0
Ask5,400.00 x 0
Day's Range5,305.50 - 5,400.00
52 Week Range2,800.00 - 6,178.50
Volume456
Avg. Volume1,358
Market Cap32.085T
Beta (5Y Monthly)0.34
PE Ratio (TTM)0.56
EPS (TTM)9,632.76
Earnings DateN/A
Forward Dividend & Yield67.26 (1.25%)
Ex-Dividend DateSep 14, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MRK.BA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Motley Fool

      What This News Means for Merck

      In combination with Roche's (OTC: RHHBY) bevacizumab (Avastin), Merck's (NYSE: MRK) oncology medicine -- co-owned with AstraZeneca (NASDAQ: AZN) and known as Lynparza -- received the nod from China's National Medical Products Administration (NMPA) to treat patients with a form of advanced ovarian cancer. What led the NMPA to green-light the treatment combo?

    • Business Wire

      U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit

      RAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin hydrochloride) and JANUMET® XR (sitagliptin and metformin hydrochloride extended-release

    • Reuters

      Merck wins ruling upholding diabetes-treatment patent at U.S. appeals court

      A Merck Sharp & Dohme Corp patent related to its diabetes drugs Januvia and Janumet is valid, a U.S. appeals court said Thursday, rejecting a challenge to the patent by generic drugmaker Mylan Pharmaceuticals Inc. Viatris Inc's Mylan failed to convince the U.S. Court of Appeals for the Federal Circuit that the patent was invalid based on an earlier patent and other publications.

    Advertisement
    Advertisement